ATS/CHEST comment on Anthem FENO coverage policy
This week, ATS and Chest sent a joint letter to health insurer Anthem expressing concerns with their draft coverage policy for FENO monitoring for the treatment of asthma and other reactive airway diseases. The draft policy issued by Anthem hold that FENO is experimental and, therefore, is not a covered service under Anthem policy. In the joint letter, ATS and CHEST state that FENO is not experimental and note the clinical practice guidelines supporting the use of FENO – including the 2011 ATS FENO guidelines - and that the Medicare program alone paid over 100,000 claims for FENO tests in 2017.
Last Reviewed: November 16, 2018
